2018
Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching ‘liquid biopsy’ and quantitative tumor modeling
Ng S, Bahig H, Wang J, Cardenas C, Lucci A, Hall C, Meas S, Sarli V, Yuan Y, Urbauer D, Ding Y, Ikner S, Dinh V, Elgohari B, Johnson J, Skinner H, Gunn G, Garden A, Phan J, Rosenthal D, Morrison W, Frank S, Hutcheson K, Mohamed A, Lai S, Ferrarotto R, MacManus M, Fuller C. Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching ‘liquid biopsy’ and quantitative tumor modeling. BMC Cancer 2018, 18: 903. PMID: 30231854, PMCID: PMC6148797, DOI: 10.1186/s12885-018-4808-5.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersClinical ProtocolsFemaleHead and Neck NeoplasmsHumansImage Processing, Computer-AssistedImaging, Three-DimensionalLiquid BiopsyMagnetic Resonance ImagingMaleNeoplastic Cells, CirculatingPositron Emission Tomography Computed TomographyPositron-Emission TomographyPrognosisProspective StudiesTreatment OutcomeConceptsNeck cancerPET/CT imagesTreatment responseBlood samplesTumor cellsTumor cell measurementUtility of CTCsProspective observational studyBackgroundMagnetic resonance imagingSoft tissue involvementDate of enrollmentSerial MR imagingDe-escalation strategiesPersonalization of treatmentEDTA blood samplesCirculating Tumor CellsCTC assessmentMucosal headClinical outcomesDose escalationImaging changesLocal therapyPretreatment CTPatient selectionPrognostic value
2017
Cost of surveillance imaging in head and neck cancer patients treated with definitive radiotherapy.
Ng S, Jomaa M, Pollard C, Ayoub Z, Mohamed A, Garden A, Berends J, Gunn G, Frank S, Skinner H, Phan J, Rosenthal D, Morrison W, Johnson J, Sturgis E, Lai S, Fuller C. Cost of surveillance imaging in head and neck cancer patients treated with definitive radiotherapy. Journal Of Clinical Oncology 2017, 35: 6610-6610. DOI: 10.1200/jco.2017.35.15_suppl.6610.Peer-Reviewed Original ResearchNeck cancer patientsSalvageable recurrenceAsymptomatic patientsDefinitive radiotherapyOverall survivalClinical findingsCancer patientsAdverse clinical findingsEarly salvage treatmentRecurrence-related deathsSuccessful salvage rateDisease-free intervalMedian overall survivalGroup of patientsChemotherapy useEligible patientsLR relapseSalvage therapyDistant relapseSalvage treatmentDisease recurrenceSalvage rateClinical outcomesMedian timeMean age